Moderna, Merck Stocks Surge on Melanoma Vaccine Trial Success

Moderna and Merck announced positive results from a late-stage clinical trial of a personalized mRNA cancer vaccine on Wednesday, August 19, 2026, sending shares of both pharmaceutical companies sharply higher.